{"id":"group-2-in-part-b-and-part-c","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06918002","NCT03439514","NCT00323297","NCT01210495","NCT05712460","NCT01856595","NCT05375929","NCT05571839","NCT03975647","NCT01045863","NCT04801420","NCT02880371","NCT07489066","NCT02603432","NCT04389632","NCT03334851","NCT01277523","NCT01623752","NCT03915496","NCT05574010","NCT02780167","NCT01925274","NCT00630487","NCT07227415","NCT01920061"],"aliases":[],"patents":[],"pricing":[],"allNames":"group 2 in part b and part c","offLabel":[],"timeline":[{"date":"2008","type":"negative","milestone":"Phase 3 Initiated","description":"Phase 3 trial (Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency) — Growth Hormone Deficiency. Trial terminated early."},{"date":"2010","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunte) — Healthy. Trial terminated early."},{"date":"2013","type":"neutral","milestone":"Phase 4 Initiated","description":"Phase 4 trial (Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Ar) — Pulmonary Arterial Hypertension"},{"date":"2014","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma) — Hepatocellular Carcinoma"}],"brandName":"Group 2 in Part B and Part C","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Dose 3 KAN-101 Intravenous (IV) infusion","explanation":"","oneSentence":"Dose 3 KAN-101 Intravenous (IV) infusion","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"group-2-in-part-b-and-part-c","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Celiac Disease","phase":"discontinued","trialId":"","patients":null,"diseaseId":"gastroenterology---hepatology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06918002","phase":"discontinued","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After ","status":"discontinued","sponsor":"Intergroupe Francophone du Myelome","isPivotal":false,"enrollment":824,"indication":"Multiple Myeloma, Newly Diagnosed","completionDate":"2036-05","primaryEndpoint":"This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT."},{"nctId":"NCT03439514","phase":"discontinued","title":"A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a La","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":77,"indication":"Dilated Cardiomyopathy","completionDate":"2022-10","primaryEndpoint":"This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA)."},{"nctId":"NCT00323297","phase":"discontinued","title":"Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Ar","status":"discontinued","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":105,"indication":"Pulmonary Arterial Hypertension","completionDate":"2013-08","primaryEndpoint":"To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy."},{"nctId":"NCT01210495","phase":"discontinued","title":"Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":224,"indication":"Hepatocellular Carcinoma","completionDate":"2014-03","primaryEndpoint":"The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma."},{"nctId":"NCT05712460","phase":"discontinued","title":"A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"Respiratory Syncytial Viruses","completionDate":"2023-04","primaryEndpoint":"This study is seeking healthy participants who are: 1."},{"nctId":"NCT01856595","phase":"discontinued","title":"PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":117,"indication":"Diabetes Mellitus, Type 2","completionDate":"2014-01","primaryEndpoint":"The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-06291874 in Type 2 Diabetes patients."},{"nctId":"NCT05375929","phase":"discontinued","title":"A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":200,"indication":"Atopic Dermatitis","completionDate":"2023-06","primaryEndpoint":"The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in I"},{"nctId":"NCT05571839","phase":"discontinued","title":"A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors","status":"discontinued","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":41,"indication":"Cutaneous Melanoma","completionDate":"2026-06","primaryEndpoint":"This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body."},{"nctId":"NCT03975647","phase":"discontinued","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients ","status":"discontinued","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":466,"indication":"HER2-positive Breast Cancer","completionDate":"2023-06","primaryEndpoint":"This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast"},{"nctId":"NCT01045863","phase":"discontinued","title":"To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunte","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":10,"indication":"Healthy","completionDate":"2010-06","primaryEndpoint":"The purpose of this study is to evaluate safety and tolerability after a single administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and biological activity."},{"nctId":"NCT04801420","phase":"discontinued","title":"Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adu","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":625,"indication":"Lyme Borreliosis","completionDate":"2022-03","primaryEndpoint":"VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B)."},{"nctId":"NCT02880371","phase":"discontinued","title":"A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced So","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":82,"indication":"Advanced Solid Tumors","completionDate":"2019-09","primaryEndpoint":"This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in adult patients"},{"nctId":"NCT07489066","phase":"discontinued","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Loca","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":120,"indication":"Carcinoma","completionDate":"2028-08","primaryEndpoint":"This study is being done to learn more about a new medicine called PF-08634404."},{"nctId":"NCT02603432","phase":"discontinued","title":"A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladd","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":700,"indication":"Urothelial Cancer","completionDate":"2019-10","primaryEndpoint":"The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with loc"},{"nctId":"NCT04389632","phase":"discontinued","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","status":"discontinued","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":1006,"indication":"Carcinoma, Non-Small Cell Lung","completionDate":"2027-06","primaryEndpoint":"This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors."},{"nctId":"NCT03334851","phase":"discontinued","title":"Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythemato","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":74,"indication":"Systemic Lupus Erythematosus","completionDate":"2022-02","primaryEndpoint":"This is a Phase 1 single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06835375 in subjects with seropositive SLE or RA."},{"nctId":"NCT01277523","phase":"discontinued","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe","status":"discontinued","sponsor":"Boehringer Ingelheim","isPivotal":false,"enrollment":392,"indication":"Asthma","completionDate":"2013-10","primaryEndpoint":"The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo,"},{"nctId":"NCT01623752","phase":"discontinued","title":"Prospective Evaluation of the Radiographic Efficacy of Enbrel","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":1821,"indication":"Rheumatoid Arthritis","completionDate":"2018-03","primaryEndpoint":"It is known from the COMET-trial that patients who start Enbrel treatment early have a great chance of reaching clinical remission and radiographic nonprogression."},{"nctId":"NCT03915496","phase":"discontinued","title":"Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic De","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":46,"indication":"Atopic Dermatitis","completionDate":"2021-11","primaryEndpoint":"B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from base"},{"nctId":"NCT05574010","phase":"discontinued","title":"A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease","status":"discontinued","sponsor":"Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA","isPivotal":false,"enrollment":128,"indication":"Celiac Disease","completionDate":"2024-11","primaryEndpoint":"This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD)."},{"nctId":"NCT02780167","phase":"discontinued","title":"Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":269,"indication":"Atopic Dermatitis","completionDate":"2017-03","primaryEndpoint":"Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety"},{"nctId":"NCT01925274","phase":"discontinued","title":"A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS W","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":19,"indication":"Metastatic Colorectal Cancer","completionDate":"2016-04","primaryEndpoint":"This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compare"},{"nctId":"NCT00630487","phase":"discontinued","title":"Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":9,"indication":"Growth Hormone Deficiency","completionDate":"2008-10","primaryEndpoint":"The study will investigate the effect on growth hormone replacement in patients with isolated growth hormone deficiency on body composition, especially visceral fat mass."},{"nctId":"NCT07227415","phase":"discontinued","title":"A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Ant","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":224,"indication":"Carcinoma, Renal Cell","completionDate":"2027-11","primaryEndpoint":"This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby t"},{"nctId":"NCT01920061","phase":"discontinued","title":"A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":110,"indication":"Neoplasm","completionDate":"2020-01","primaryEndpoint":"This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL2108943"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","aiSummary":"Due to the provided information, a clinical summary cannot be created. The drug 'group-2-in-part-b-and-part-c' has a discontinued phase and lacks information on its mechanism and indications. Therefore, a factual and concise summary is impossible.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}